Target intelligence / Profile preview

Rapamycin-insensitive companion of mTOR (RICTOR) (RICTOR)

Target
RICTOR
Molecular classification
Scaffold protein, Multiprotein complex subunit, Other
01

Overview

Rapamycin-insensitive companion of mTOR (RICTOR) is an essential, defining subunit of the mechanistic target of rapamycin complex 2 (mTORC2). Unlike mTORC1, mTORC2 is insensitive to acute rapamycin treatment and plays a distinct role in regulating cell survival, proliferation, metabolism, and cytoskeletal organization. RICTOR acts as a critical scaffold protein within mTORC2, facilitating the phosphorylation and activation of AGC kinase family members, most notably AKT at Ser473, which is a key step for full AKT activation. Aberrant activation of RICTOR, frequently driven by RICTOR gene amplification or protein overexpression, is implicated in various malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, and glioblastoma, where it promotes tumor growth, metastasis, and resistance to therapy. Consequently, RICTOR and the mTORC2 complex have emerged as attractive therapeutic targets. While direct, selective inhibitors of RICTOR are primarily in preclinical development (such as JR-AB2-011, which disrupts the Rictor-mTOR interaction), dual mTORC1/2 inhibitors like vistusertib and sapanisertinib have been evaluated in clinical trials for patients with RICTOR-amplified solid tumors.

Other names
RPTOR independent companion of MTOR complex 2AVO3 homologhAVO3KIAA1999PIA
02

Mechanism of action

mTORC1/mTORC2 dual inhibition, mTORC2-specific inhibition, and disruption of Rictor-mTOR protein-protein interaction

03

Biological functions

Signal transductionCell growthCell proliferationCell survivalCytoskeletal organizationMetabolism
04

Disease associations

CancerDiabetesObesityNeurodegenerative disease
05

Safety considerations

HyperglycemiaHyperlipidemiaGastrointestinal toxicityFatigueImmunosuppressionIncomplete inhibition due to feedback loopsToxicity from dual mTORC1/2 inhibition
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

RICTOR gene amplificationRictor protein overexpressionAKT phosphorylation (Ser473)p-mTORp-S6

Beyond the preview

Go deeper on Rapamycin-insensitive companion of mTOR (RICTOR) (RICTOR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapamycin-insensitive companion of mTOR (RICTOR) (RICTOR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call